As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Palomino Laboratories Inc. The largest reported stake is Shealy Jeffrey B.'s, at 23.8%. 6 filings are on record since October 6, 2025 (Schedule 13D, October 27, 2025).
Sell to companies like Palomino Laboratories Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Richard Ogawa · Sole voting: 1,882,500 · Shared voting: 0 · Sole dispositive: 1,882,500 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-21
- · Holder: Shealy Jeffrey B. · Percent: 23.8% · SCHEDULE 13D
- · Holder: Richard Ogawa · Percent: 9.4% · SCHEDULE 13D
- · Holder: Steven DenBaars · Percent: 9.4% · SCHEDULE 13D
- · Holder: Lucius Partners LLC · Percent: 100% · SCHEDULE 13D
Palomino Laboratories Inc. has 6 Schedule 13D or 13G filings on record since 2025-10-06. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 23.8% | 4,666,666 | SCHEDULE 13D, 2025-10-27 | 2025-09-29 | |
| Lucius Partners LLC | 23% | 4,000,000 | SCHEDULE 13D/A, 2025-10-06 | 2025-09-29 |
| 9.4% | 1,750,000 | SCHEDULE 13D, 2025-10-07 | 2025-09-29 | |
| 6.9% | 1,882,500 | SCHEDULE 13D/A, 2026-08-21 | 2026-07-31 |
Holding shares or following this stake? See who's behind Palomino Laboratories Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Palomino Laboratories Inc. and the records around it.
The people at Palomino Laboratories Inc.
- Jeffrey Shealy and Richard Ogawa are also named on 1 other Form D filing: Blue Laser Fusion, Inc. (Oct 2026)
Palomino Laboratories Inc. elsewhere on the record
- Company profile and every filing May 2026
- Form D filing May 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Matthew Eitner also filed stake reports on 1 other company: Blue Laser Fusion, Inc. (Sep 2026)
- Richard Ogawa also filed stake reports on 1 other company: Blue Laser Fusion, Inc. (Sep 2026)
Watch Palomino Laboratories Inc.
Get an email when Palomino Laboratories Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Palomino Laboratories Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Palomino Laboratories Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Palomino Laboratories Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Richard Ogawa | 1,882,500 | 0 | 1,882,500 | 0 | SCHEDULE 13D/A, 2026-08-21 |
The latest filing identifies Palomino Laboratories Inc. by CUSIP 909233108 and gives its principal executive office as 130 Castilian Drive, Suite 102, Goleta, CA 93117 (SCHEDULE 13D/A, 2026-08-21).
Source of funds (Item 3)
Item 3 is being amended and supplemented by adding the following: On July 31, 2026, pursuant to the terms of a Share Exchange Agreement and Plan of Reorganization (the "Share Exchange Agreement") by and among the Issuer, Vega Links, Inc. ("VLI"), and VLI's stockholders (the "Stockholders"), the Stockholders who directly owned all of the issued and outstanding equity interests of VLI amounting to 11,180,000 shares of common stock (the "Shares"), exchanged all the Shares for 4,472,000 shares of the Palomino Common Stock.Richard Ogawa, SCHEDULE 13D/A, 2026-08-21
Purpose of Transaction (Item 4)
Steven DenBaars
The Reporting Person acquired the Common Stock in connection with the Merger and the Offering. The information contained in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as a director of the Issuer. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of this Schedule 13D. Subject to the Lock-Up Agreement described in Item 6 of this Schedule 13D, the Reporting Person may, from time to time, purchase or sell securities of the Issuer as appropriate for his personal circumstances. Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of this Schedule 13D. The Reporting Person reserves the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of this Schedule 13D.Item 4 of the SCHEDULE 13D filed 2025-10-07
Richard Ogawa
The Reporting Person acquired the Consideration Shares pursuant to the Share Exchange Agreement. The information contained in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as the Secretary and a director of the Issuer. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of this Schedule 13D. Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of this Schedule 13D. The Reporting Person reserves the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of this Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-21
Shealy Jeffrey B.
The Reporting Person acquired the Common Stock in connection with the Merger and the Offering. The information contained in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as the Chief Executive Officer, President and a director of the Issuer. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of this Schedule 13D. Subject to the Lock-Up Agreement described in Item 6 of this Schedule 13D, the Reporting Person may, from time to time, purchase or sell securities of the Issuer as appropriate for his personal circumstances. Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of this Schedule 13D. The Reporting Person reserves the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of this Schedule 13D.Item 4 of the SCHEDULE 13D filed 2025-10-27
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-06 | Lucius Partners LLC | 100% | SCHEDULE 13D |
| 2025-10-06 | Lucius Partners LLC | 23% | SCHEDULE 13D/A |
| 2025-10-07 | Steven DenBaars | 9.4% | SCHEDULE 13D |
| 2025-10-08 | Richard Ogawa | 9.4% | SCHEDULE 13D |
| 2025-10-27 | Shealy Jeffrey B. | 23.8% | SCHEDULE 13D |
| 2026-08-21 | Richard Ogawa | 6.9% | SCHEDULE 13D/A |
Questions about who owns Palomino Laboratories Inc.
Who owns Palomino Laboratories Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Palomino Laboratories Inc.: Shealy Jeffrey B. (23.8%, Schedule 13D, filed 2025-10-27), Lucius Partners LLC (23%, Schedule 13D/A, filed 2025-10-06), Steven DenBaars (9.4%, Schedule 13D, filed 2025-10-07) and Richard Ogawa (6.9%, Schedule 13D/A, filed 2026-08-21).
Who are the largest shareholders of Palomino Laboratories Inc.?
By the share each holder's latest filing reports, the largest holders of Palomino Laboratories Inc. on this page are Shealy Jeffrey B. (23.8%), Lucius Partners LLC (23%) and Steven DenBaars (9.4%).
When did Shealy Jeffrey B. buy into Palomino Laboratories Inc.?
The filings give report dates, not purchase dates. The earliest filing from Shealy Jeffrey B. on this page is the Schedule 13D, filed 2025-10-27, reporting 23.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Palomino Laboratories Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 1, 2026 | Form D, private offering | $16.98M sold | Form D page | Source |
| October 14, 2025 | Form D, private offering | $11.60M sold | Form D page | Source |
Palomino Laboratories Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Palomino Laboratories Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.